SCHEMBL3604417

SCHEMBL3604417

CC(=O)n1ccc(N)n1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1044057 0.80
SCHEMBL4106091 0.80
SCHEMBL13101034 0.78 MAPT (0.33)
SCHEMBL12126287 0.76
SCHEMBL306662 0.74 HSP90AA1 (0.39)
Acetamide SCHEMBL1483478 0.72 KEAP1 (0.42)
SCHEMBL17489137 0.72 ALOX15 (0.50)
SCHEMBL13924793 0.71 KDM4C (0.40)
SCHEMBL22057261 0.71 ALOX15 (0.36)
SCHEMBL18397623 0.71 ALOX15 (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210355221-A1 Targeting the Non-Canonical NFkB Pathway in Cancer Immunotherapy THE GENERAL HOSPITAL CORPORATION 2021-11-18 US claimed
WO-2020082016-A1 TARGETING THE NON-CANONICAL NFKB PATHWAY IN CANCER IMMUNOTHERAPY THE GENERAL HOSPITAL CORPORATION (US) 2020-04-23 WO claimed
EP-4399202-A1 SUBSTITUTED QUINOLINES AS IMPROVED NF-KB-INDUCING KINASE (NIK) INHIBITORS Yukin Therapeutics (FR) 2024-07-17 EP disclosed
WO-2023072962-A1 SUBSTITUTED QUINOLINES AS IMPROVED NF-KB-INDUCING KINASE (NIK) INHIBITORS Yukin Therapeutics (FR) 2023-05-04 WO disclosed
EP-4169904-A1 SUBSTITUTED QUINOLINES AS IMPROVED NF-KB-INDUCING KINASE (NIK) INHIBITORS Yukin Therapeutics (FR) 2023-04-26 EP disclosed
CN-112062754-B Preparation method of intermediate for synthesizing Dorzagliatin 深圳市华先医药科技有限公司 2022-06-21 CN disclosed
US-20210355221-A1 Targeting the Non-Canonical NFkB Pathway in Cancer Immunotherapy THE GENERAL HOSPITAL CORPORATION 2021-11-18 US disclosed
CN-112062754-A Preparation method of intermediate for synthesizing Dorzagliatin 深圳市华先医药科技有限公司 2020-12-11 CN disclosed
WO-2020082016-A1 TARGETING THE NON-CANONICAL NFKB PATHWAY IN CANCER IMMUNOTHERAPY THE GENERAL HOSPITAL CORPORATION (US) 2020-04-23 WO disclosed
EP-1600442-B1 HETEROARYLCARBAMOYLBENZENE DERIVATIVE MSD KK (JP) 2018-01-17 EP disclosed
US-8530646-B2 Oxazolidinone derivative having 7-membered hetero ring RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2013-09-10 US disclosed
EP-2208729-A1 OXAZOLIDINONE DERIVATIVE HAVING 7-MEMBERED HETERO RING Research Foundation Itsuu Laboratory (JP) 2010-07-21 EP disclosed
US-7754743-B2 Heteroarylcarbamoylbenzene derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-07-13 US disclosed
CN-101712657-A heteroarylcarbamoylbenzene derivative BANYU PHARMA CO LTD 2010-05-26 CN disclosed
CN-100591671-C Heteroarylcarbamoylbenzene derivatives BANYU PHARMA CO LTD 2010-02-24 CN disclosed
US-20090018056-A1 Heteroarylcarbamoylbenzene derivatives MSD K.K. (JP) 2009-01-15 US disclosed
US-7432287-B2 Heteroarylcarbamoylbenzene derivative BANYU PHARMECEUTICAL CO., LTD. (JP) 2008-10-07 US disclosed
US-20060167053-A1 Heteroarylcarbamoylbenzene derivative MSD K.K. (JP) 2006-07-27 US disclosed
CN-1777589-A Heteroarylcarbamoylbenzene derivatives BANYU PHARMA CO LTD (JP) 2006-05-24 CN disclosed
EP-1600442-A1 HETEROARYLCARBAMOYLBENZENE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2005-11-30 EP disclosed